278 related articles for article (PubMed ID: 12686817)
1. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG; Pileblad E
J Urol; 2003 May; 169(5):1720-3. PubMed ID: 12686817
[TBL] [Abstract][Full Text] [Related]
2. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
Roobol MJ; van der Cruijsen IW; Schröder FH
Urology; 2004 May; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
[TBL] [Abstract][Full Text] [Related]
3. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
Hosseini SY; Moharramzadeh M; Ghadian AR; Hooshyar H; Lashay AR; Safarinejad MR
Int J Urol; 2007 May; 14(5):406-11. PubMed ID: 17511722
[TBL] [Abstract][Full Text] [Related]
4. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
Roobol MJ; Roobol DW; Schröder FH
Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
[TBL] [Abstract][Full Text] [Related]
5. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
6. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
Mäkinen T; Tammela TL; Hakama M; Stenman UH; Rannikko S; Aro J; Juusela H; Määttänen L; Auvinen A
J Urol; 2001 Oct; 166(4):1339-42. PubMed ID: 11547069
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
Roobol MJ; Kranse R; de Koning HJ; Schröder FH
Urology; 2004 Feb; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
[TBL] [Abstract][Full Text] [Related]
8. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Schröder FH; Raaijmakers R; Postma R; van der Kwast TH; Roobol MJ
J Urol; 2005 Aug; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
[TBL] [Abstract][Full Text] [Related]
9. Significance of serum free prostate specific antigen in the screening of prostate cancer.
Higashihara E; Nutahara K; Kojima M; Okegawa T; Miura I; Miyata A; Kato M; Sugisaki H; Tomaru T
J Urol; 1996 Dec; 156(6):1964-8. PubMed ID: 8911366
[TBL] [Abstract][Full Text] [Related]
10. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
Zackrisson B; Aus G; Bergdahl S; Lilja H; Lodding P; Pihl CG; Hugosson J
J Urol; 2004 Apr; 171(4):1500-3. PubMed ID: 15017207
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen change in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
Raaijmakers R; Wildhagen MF; Ito K; Pàez A; de Vries SH; Roobol MJ; Schröder FH
Urology; 2004 Feb; 63(2):316-20. PubMed ID: 14972481
[TBL] [Abstract][Full Text] [Related]
12. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
Hugosson J; Aus G; Lilja H; Lodding P; Pihl CG
Cancer; 2004 Apr; 100(7):1397-405. PubMed ID: 15042673
[TBL] [Abstract][Full Text] [Related]
13. Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.
Crawford ED; Pinsky PF; Chia D; Kramer BS; Fagerstrom RM; Andriole G; Reding D; Gelmann EP; Levin DL; Gohagan JK
J Urol; 2006 Apr; 175(4):1286-90; discussion 1290. PubMed ID: 16515981
[TBL] [Abstract][Full Text] [Related]
14. Relationship among initial serum prostate specific antigen, prostate specific antigen progression and prostate cancer detection at repeat screening visits.
Candas B; Labrie F; Gomez JL; Cusan L; Chevrette E; Lévesque J; Brousseau G
J Urol; 2006 Feb; 175(2):510-6; discussion 516-7. PubMed ID: 16406983
[TBL] [Abstract][Full Text] [Related]
15. Possibility of re-screening intervals of more than one year in men with PSA levels of 4.0 ng/ml or less.
Ito K; Yamamoto T; Ohi M; Takechi H; Kurokawa K; Suzuki K; Yamanaka H
Prostate; 2003 Sep; 57(1):8-13. PubMed ID: 12886518
[TBL] [Abstract][Full Text] [Related]
16. Serial biopsy results in prostate cancer screening study.
Roehl KA; Antenor JA; Catalona WJ
J Urol; 2002 Jun; 167(6):2435-9. PubMed ID: 11992052
[TBL] [Abstract][Full Text] [Related]
17. Long term follow-up of mass screening for prostate carcinoma in men with initial prostate specific antigen levels of 4.0 ng/ml or less.
Ito K; Kubota Y; Yamamoto T; Suzuki K; Fukabori Y; Kurokawa K; Yamanaka H
Cancer; 2001 Feb; 91(4):744-51. PubMed ID: 11241242
[TBL] [Abstract][Full Text] [Related]
18. [An experience of individual and early diagnosis of prostate cancer in a Tunisian centre].
Khouaja K; Ben Sorba N; Bouslama A; Youssef A; Taher Mosbah A
Prog Urol; 2005 Apr; 15(2):255-9. PubMed ID: 15999603
[TBL] [Abstract][Full Text] [Related]
19. Comparison of different prostate-specific antigen cutpoints for early detection of prostate cancer: results of a large screening study.
Reissigl A; Pointner J; Horninger W; Ennemoser O; Strasser H; Klocker H; Bartsch G
Urology; 1995 Nov; 46(5):662-5. PubMed ID: 7495117
[TBL] [Abstract][Full Text] [Related]
20. Are repeat biopsies required in men with PSA levels < or =4 ng/ml? A Multiinstitutional Prospective European Study.
Djavan B; Fong YK; Ravery V; Remzi M; Horninger W; Susani M; Kreuzer S; Boccon-Gibod L; Bartsch G; Marberger M
Eur Urol; 2005 Jan; 47(1):38-44; discussion 44. PubMed ID: 15582247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
